Peter J Ferguson

Summary

Affiliation: University of Western Ontario
Country: Canada

Publications

  1. ncbi In vivo inhibition of growth of human tumor lines by flavonoid fractions from cranberry extract
    Peter J Ferguson
    London Regional Cancer Program, Health Sciences Centre, 790 Commissioners Road East, London, Ontario, Canada
    Nutr Cancer 56:86-94. 2006
  2. ncbi A flavonoid fraction from cranberry extract inhibits proliferation of human tumor cell lines
    Peter J Ferguson
    Department of Physiology and Pharmacology, University of Western Ontario, London, ON, Canada
    J Nutr 134:1529-35. 2004
  3. ncbi Enhancement of cytotoxicity of natural product drugs against multidrug resistant variant cell lines of human head and neck squamous cell carcinoma and breast carcinoma by tesmilifene
    Peter J Ferguson
    Lawson Health Research Institute, London Health Sciences Centre, 790 Commissioners Road, London, Ontario, Canada
    Cancer Lett 274:279-89. 2009
  4. ncbi Tangeretin and nobiletin induce G1 cell cycle arrest but not apoptosis in human breast and colon cancer cells
    Karen L Morley
    Cancer Research Laboratory Program, London Regional Cancer Program, Lawson Health Research Institute, London Health Sciences Centre, London, Ont, Canada
    Cancer Lett 251:168-78. 2007
  5. ncbi ODN 491, a novel antisense oligodeoxynucleotide that targets thymidylate synthase, exerts cell-specific effects in human tumor cell lines
    Tracey L H Jason
    London Regional Cancer Program, London Health Sciences Centre, London, Ontario, Canada
    DNA Cell Biol 27:229-40. 2008
  6. ncbi A "combination oligonucleotide" antisense strategy to downregulate thymidylate synthase and decrease tumor cell growth and drug resistance
    Randal W Berg
    Cancer Research Laboratories, London Regional Cancer Centre, 790 Commissioners Road, London, Ontario, Canada N6A 4L6
    Cancer Gene Ther 10:278-86. 2003

Collaborators

  • Ann F Chambers
  • E M Kurowska
  • Randal W Berg
  • Tracey L H Jason
  • James Koropatnick
  • Karen L Morley
  • Mark D Vincent
  • Rene Figueredo
  • D James Koropatnick

Detail Information

Publications6

  1. ncbi In vivo inhibition of growth of human tumor lines by flavonoid fractions from cranberry extract
    Peter J Ferguson
    London Regional Cancer Program, Health Sciences Centre, 790 Commissioners Road East, London, Ontario, Canada
    Nutr Cancer 56:86-94. 2006
    ..05) and also induce cell death within 24 to 48 h of exposure (P < 0.05). These results indicate the presence of a potential anticancer constituent in the flavonoid-containing fractions from cranberry extracts...
  2. ncbi A flavonoid fraction from cranberry extract inhibits proliferation of human tumor cell lines
    Peter J Ferguson
    Department of Physiology and Pharmacology, University of Western Ontario, London, ON, Canada
    J Nutr 134:1529-35. 2004
    ..05) and induce cells to undergo apoptosis (P < 0.05) in a dose-dependent manner. Fr6 is potentially a source of a novel anticancer agent...
  3. ncbi Enhancement of cytotoxicity of natural product drugs against multidrug resistant variant cell lines of human head and neck squamous cell carcinoma and breast carcinoma by tesmilifene
    Peter J Ferguson
    Lawson Health Research Institute, London Health Sciences Centre, 790 Commissioners Road, London, Ontario, Canada
    Cancer Lett 274:279-89. 2009
    ..The results suggest that tesmilifene might be effective in the treatment of tumors that are resistant to natural product drugs. The mechanism of enhancement appears to be related to expression of an ABC pump-dependent, MDR phenotype...
  4. ncbi Tangeretin and nobiletin induce G1 cell cycle arrest but not apoptosis in human breast and colon cancer cells
    Karen L Morley
    Cancer Research Laboratory Program, London Regional Cancer Program, Lawson Health Research Institute, London Health Sciences Centre, London, Ont, Canada
    Cancer Lett 251:168-78. 2007
    ..Inhibition of proliferation of human cancers without inducing cell death may be advantageous in treating tumors as it would restrict proliferation in a manner less likely to induce cytotoxicity and death in normal, non-tumor tissues...
  5. ncbi ODN 491, a novel antisense oligodeoxynucleotide that targets thymidylate synthase, exerts cell-specific effects in human tumor cell lines
    Tracey L H Jason
    London Regional Cancer Program, London Health Sciences Centre, London, Ontario, Canada
    DNA Cell Biol 27:229-40. 2008
    ..Recognition of tumor cell-specific and mRNA region-specific variability in response to AS TS ODNs will be important in designing AS TS ODNs for potential clinical use...
  6. ncbi A "combination oligonucleotide" antisense strategy to downregulate thymidylate synthase and decrease tumor cell growth and drug resistance
    Randal W Berg
    Cancer Research Laboratories, London Regional Cancer Centre, 790 Commissioners Road, London, Ontario, Canada N6A 4L6
    Cancer Gene Ther 10:278-86. 2003
    ..The results are evidence that the novel use of multiple antisense ODNs that target different regions of the same mRNA represents a general strategy to improve antisense effectiveness...